Evidence map›Paper›PMID 41877621›Full record

ArticleAnnals of medicine2026

Adverse drug reactions among children with tuberculosis in China: a multicentre study, 2017-2022.

Yiqing Zhou, Yu Kan, Ping Liu, Hongmei Xu, Juan Ma, Haiyan Li, Xin Yu, Qingshan Cai, Man Tian, Qing Fang and 6 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yiqing ZhouSchool of Public Health, Hangzhou Medical College, Hangzhou, China.
Yu KanThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Ping LiuDepartment of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Hongmei XuDivision of Infectious Diseases, Chongqing Medical University Affiliated Children's Hospital, Chongqing, China.
Juan MaDepartment of Infectious Diseases, Qinghai Province Women and Children's Hospital, Xining, China.
Haiyan LiDepartment of Pediatric Pulmonology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
Xin YuDepartment of Tuberculosis, Suzhou No. 5 People's Hospital, Suzhou, China.
Qingshan CaiDepartment of Tuberculosis, Hangzhou Red Cross Hospital, Hangzhou, China.
Man TianDepartment of Respiratory Medicine, Children's Hospital of Nanjing Medical University, Nanjing, China.
Qing FangDepartment of Pulmonary Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Xianhui ZengDepartment of Infectious Diseases, Hainan Women and Children's Medical Center, Haikou, China.
Guangxu YangTuberculosis Prevention Institute, Changchun Infectious Disease Hospital, Changchun, China.
Tao YangScientific Research Center, Zhejiang Sukean Pharmaceutical Co. Ltd., Hangzhou, China.
Fei WangDepartment of Tuberculosis Control and Prevention, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.ORCID 0000-0001-8997-8619
Bin ChenDepartment of Tuberculosis Control and Prevention, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.ORCID 0000-0002-3761-0465
Leonardo MartinezDepartment of Epidemiology, Boston University School of Public Health, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAlthough tuberculosis (TB) treatment, if adequately taken and adhered to, is highly effective. To investigate the occurrence, frequency and related factors of adverse drug reactions (ADRs) during anti-TB treatment in children in China.

methodsWe conducted a multicentre study and collected data from 11 representative paediatric specialists and general hospitals offering anti-TB treatment. The outcome of interest was the occurrence of any ADRs. Multivariable logistic regression was performed to explore factors associated with ADRs and to identify groups at high-risk for ADRs.

resultsIn total, 482 patients were enrolled; of whom, 94 (19%) reported an ADR. The most common ADRs were blood system damage (24%) and gastrointestinal reactions (24%). Most ADRs occurred within the intensive treatment period and were of short duration. Children with severe TB or those treated with HRZ(E) + second-line drugs in the intensive phase were at higher odds of developing ADRs (OR = 2.44, 95% CI: 1.36-4.39,

conclusionsADRs are prevalent in Chinese paediatric TB patients, predominantly haematological or gastrointestinal, transient during the intensive phase. Severe disease and HRZ(E) + second-line regimens confer elevated risk, necessitating targeted surveillance and optimized paediatric therapies balancing efficacy and safety.

Indexed as

Antitubercular AgentsDrug-Related Side Effects and Adverse ReactionsTuberculosisAdolescentChildChild, PreschoolChinaFemaleHumansInfantMaleRisk FactorsAntitubercular Agentsadverse drug reactionschildrenChinamulticentreTuberculosis

Identifiers

PMID41877621
PMCPMC13021018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.